Included in the formulation
АТХ:D.01.A.E.22 Naphthyfin
Pharmacodynamics:The drug reduces the synthesis of ergosterol, which is a component of the cell membrane, inhibiting squalene-2,3-epoxidase, resulting in a fungal cell there is accumulation of squalene. Naphthyfin, penetrating the horny layer of the skin, has a fungicidal and fungistatic effect, thus reducing inflammation and itching. Effective in relation to Trichophyton spp. (T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum, T. tonsurans), Microsporum canis, Epidermophyton floccosum, molds (mainly C. albicans), Pityrosporum orbiculare. Ineffective against bacteria, rickettsia and viruses.
Pharmacokinetics:Absorption from skin - 4-6%. Biotransformation in the liver. The half-life is 2-3 days. Elimination of kidneys and feces in the form of unchanged substance and metabolites.
Indications:Dermatophytosis, including mycosis stop. Candidiasis of the skin.Pityriasis (multicolored) deprive.
I.B35-B49.B35 Dermatophytosis
I.B35-B49.B35.3 Mycosis of the feet
I.B35-B49.B35.2 Mycosis brushes
I.B35-B49.B35.1 Mycosis of nails
I.B35-B49.B35.6 Epidermophytosis inguinal
I.B35-B49.B36.0 Multicolored lichen
I.B35-B49.B37.2 Candidiasis of skin and nails
I.B35-B49.B49 Mycosis, unspecified
VIII.H60-H62.H62.2 * External otitis with fungal infections
Contraindications:Individual intolerance, including propylene glycol - for the solution, benzyl alcohol - for the cream. Open wound surface (for solution).
Carefully:Pregnancy. Lactation. Child age (safety of use and efficacy not determined).
Pregnancy and lactation:Recommendations FDA Category B. The drug is approved for use during pregnancy and breastfeeding with caution.
Dosing and Administration:Apply in the form of 1% cream or 1% solution once a day on the affected skin, which must first be cleaned and thoroughly dried. Duration of treatment with dermatomycosis 2-4 weeks (if necessary, up to 8 weeks), with candidiasis - 4 weeks.
With onychomycosis, a cream or solution 2 times a day is applied to the affected surface, covering with a dense bandage. The course of treatment is 6 months, with complicated forms - 8 months.
To prevent recurrent infection, treatment should be continued for at least 2 weeks after recovery.
Side effects:Local irritant effect: dryness, skin hyperemia, burning, itching, redness, or other signs of skin irritation that were not present before the treatment.
Interaction:Not described.
Special instructions:The drug is not intended for use in ophthalmology. Avoid contact with the eyes.